{"organizations": [], "uuid": "7de31d884ba1daa38d6f8447276a128d0054a0f5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/03/05/the-associated-press-fate-therapeutics-reports-4q-loss.html", "country": "US", "domain_rank": 767, "title": "Fate Therapeutics reports 4Q loss", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-05T23:15:00.000+02:00", "replies_count": 0, "uuid": "7de31d884ba1daa38d6f8447276a128d0054a0f5"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/03/05/the-associated-press-fate-therapeutics-reports-4q-loss.html", "ord_in_thread": 0, "title": "Fate Therapeutics reports 4Q loss", "locations": [], "entities": {"persons": [], "locations": [{"name": "san diego", "sentiment": "none"}], "organizations": [{"name": "fate therapeutics", "sentiment": "negative"}, {"name": "fate therapeutics inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Monday reported a loss of $12.5 million in its fourth quarter.\nOn a per-share basis, the San Diego-based company said it had a loss of 29 cents.\nThe results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share.\nThe clinical-stage biotech company that develops stem cell treatments posted revenue of $1 million in the period, meeting Street forecasts.\nFor the year, the company reported that its loss widened to $43 million, or $1.02 per share. Revenue was reported as $4.1 million.\nFate Therapeutics shares have more than doubled since the beginning of the year. In the final minutes of trading on Monday, shares hit $13.83, more than tripling in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE", "external_links": [], "published": "2018-03-05T23:15:00.000+02:00", "crawled": "2018-03-06T02:09:05.016+02:00", "highlightTitle": ""}